Annual Total Liabilities
$704.26 M
-$201.93 M-22.28%
December 31, 2023
Summary
- As of February 7, 2025, PCRX annual total liabilities is $704.26 million, with the most recent change of -$201.93 million (-22.28%) on December 31, 2023.
- During the last 3 years, PCRX annual total liabilities has risen by +$49.43 million (+7.55%).
- PCRX annual total liabilities is now -47.64% below its all-time high of $1.34 billion, reached on December 31, 2021.
Performance
PCRX Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$772.11 M
+$4.57 M+0.59%
September 30, 2024
Summary
- As of February 7, 2025, PCRX quarterly total liabilities is $772.11 million, with the most recent change of +$4.57 million (+0.59%) on September 30, 2024.
- Over the past year, PCRX quarterly total liabilities has increased by +$69.20 million (+9.84%).
- PCRX quarterly total liabilities is now -42.59% below its all-time high of $1.34 billion, reached on December 31, 2021.
Performance
PCRX Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
PCRX Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -22.3% | +9.8% |
| 3 y3 years | +7.5% | -34.7% |
| 5 y5 years | +91.3% | -34.7% |
PCRX Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -47.6% | at low | -42.6% | +11.7% |
| 5 y | 5-year | -47.6% | +47.9% | -42.6% | +72.6% |
| alltime | all time | -47.6% | +1535.9% | -42.6% | +1571.3% |
Pacira BioSciences Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $772.11 M(+0.6%) |
| Jun 2024 | - | $767.54 M(+11.1%) |
| Mar 2024 | - | $691.16 M(-1.9%) |
| Dec 2023 | $704.26 M(-22.3%) | $704.26 M(+0.2%) |
| Sep 2023 | - | $702.91 M(-4.3%) |
| Jun 2023 | - | $734.41 M(-2.8%) |
| Mar 2023 | - | $755.38 M(-16.6%) |
| Dec 2022 | $906.19 M(-32.6%) | $906.19 M(-6.0%) |
| Sep 2022 | - | $964.24 M(-1.3%) |
| Jun 2022 | - | $977.35 M(-17.3%) |
| Mar 2022 | - | $1.18 B(-12.1%) |
| Dec 2021 | $1.34 B(+105.4%) | $1.34 B(+111.0%) |
| Sep 2021 | - | $637.40 M(-0.2%) |
| Jun 2021 | - | $638.66 M(+0.3%) |
| Mar 2021 | - | $636.73 M(-2.8%) |
| Dec 2020 | $654.83 M(+37.5%) | $654.83 M(+3.0%) |
| Sep 2020 | - | $635.58 M(+33.0%) |
| Jun 2020 | - | $477.96 M(+6.8%) |
| Mar 2020 | - | $447.34 M(-6.0%) |
| Dec 2019 | $476.12 M(+29.3%) | $476.12 M(+3.2%) |
| Sep 2019 | - | $461.33 M(+3.4%) |
| Jun 2019 | - | $446.19 M(+13.9%) |
| Mar 2019 | - | $391.64 M(+6.4%) |
| Dec 2018 | $368.13 M(+5.5%) | $368.13 M(+2.9%) |
| Sep 2018 | - | $357.78 M(+1.6%) |
| Jun 2018 | - | $352.17 M(+2.5%) |
| Mar 2018 | - | $343.52 M(-1.5%) |
| Dec 2017 | $348.89 M | $348.89 M(+2.2%) |
| Sep 2017 | - | $341.29 M(-1.0%) |
| Jun 2017 | - | $344.70 M(+4.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2017 | - | $329.33 M(+90.9%) |
| Dec 2016 | $172.49 M(+1.9%) | $172.49 M(+3.3%) |
| Sep 2016 | - | $167.00 M(-3.1%) |
| Jun 2016 | - | $172.35 M(+4.4%) |
| Mar 2016 | - | $165.04 M(-2.5%) |
| Dec 2015 | $169.34 M(+9.3%) | $169.34 M(+5.9%) |
| Sep 2015 | - | $159.97 M(+0.2%) |
| Jun 2015 | - | $159.71 M(+5.8%) |
| Mar 2015 | - | $151.01 M(-2.5%) |
| Dec 2014 | $154.93 M(+20.5%) | $154.93 M(+3.1%) |
| Sep 2014 | - | $150.32 M(+4.3%) |
| Jun 2014 | - | $144.11 M(+12.6%) |
| Mar 2014 | - | $127.98 M(-0.5%) |
| Dec 2013 | $128.57 M(+178.3%) | $128.57 M(+4.3%) |
| Sep 2013 | - | $123.28 M(+3.3%) |
| Jun 2013 | - | $119.29 M(+3.3%) |
| Mar 2013 | - | $115.45 M(+149.9%) |
| Dec 2012 | $46.20 M(-29.2%) | $46.20 M(-11.8%) |
| Sep 2012 | - | $52.38 M(+8.3%) |
| Jun 2012 | - | $48.35 M(-15.2%) |
| Mar 2012 | - | $57.02 M(-12.6%) |
| Dec 2011 | $65.22 M(-43.3%) | $65.22 M(+2.3%) |
| Sep 2011 | - | $63.73 M(-0.7%) |
| Jun 2011 | - | $64.16 M(-3.8%) |
| Mar 2011 | - | $66.72 M(-42.0%) |
| Dec 2010 | $114.94 M(+71.8%) | $114.94 M(+20.0%) |
| Sep 2010 | - | $95.79 M(+13.4%) |
| Jun 2010 | - | $84.47 M(+26.3%) |
| Dec 2009 | $66.90 M(+55.4%) | $66.90 M |
| Dec 2008 | $43.05 M | - |
FAQ
- What is Pacira BioSciences annual total liabilities?
- What is the all time high annual total liabilities for Pacira BioSciences?
- What is Pacira BioSciences annual total liabilities year-on-year change?
- What is Pacira BioSciences quarterly total liabilities?
- What is the all time high quarterly total liabilities for Pacira BioSciences?
- What is Pacira BioSciences quarterly total liabilities year-on-year change?
What is Pacira BioSciences annual total liabilities?
The current annual total liabilities of PCRX is $704.26 M
What is the all time high annual total liabilities for Pacira BioSciences?
Pacira BioSciences all-time high annual total liabilities is $1.34 B
What is Pacira BioSciences annual total liabilities year-on-year change?
Over the past year, PCRX annual total liabilities has changed by -$201.93 M (-22.28%)
What is Pacira BioSciences quarterly total liabilities?
The current quarterly total liabilities of PCRX is $772.11 M
What is the all time high quarterly total liabilities for Pacira BioSciences?
Pacira BioSciences all-time high quarterly total liabilities is $1.34 B
What is Pacira BioSciences quarterly total liabilities year-on-year change?
Over the past year, PCRX quarterly total liabilities has changed by +$69.20 M (+9.84%)